tbuckley/cabot-search huggingface dataset:
Relationship between the methylation status of DLC-1 gene and the metastasis of hepatocellular carcinoma
Authors: Y. Zhang, J. Liu
Journal: Journal of Clinical Oncology (2008)

15660 Background: To study the relationship between the expression level of the methylation status of Deleted Liver Cancer (DLC)-1 gene and the metastasis of hepatocellular carcinoma(HCC). Methods: According to their clinicopathological features, 73 patients of HCC were divided into high invasive group(34 cases) in which intrahepatic dissemination of cancer or cancer thrombosis in portal vein were existed and low invasive groups (41cases) in which no intrahepatic dissemination of cancer or cancer thrombosis in portal vein were seen. A methylation-specific PCR(MSP) was taken for the detection of the expression of methylation of DLC-1 gene both in surgical specimens and in blood samples from two groups. Results: The expression level of the methylation status of DLC-1 gene in HCC surgical specimens with high invasive group was significantly higher than that with low invasive group(χ2=4.3567, P < 0. 05), so was it in blood samples (χ2=4.4652, P < 0. 05));Methylation status of DLC-1 gene in both surgical specimens and serum of liver cancer patients were relevant to their clinical stage((χ2=10.8478, P < 0. 05); There was a significant difference in The Median Survival Time between patients of HCC with the expression of Methylated DLC-1gene and the patients without the expression of the Methylated DLC-1gene ( P < 0. 05). Conclusions: The expression level of the methylation Status of DLC-1 gene may be relevant to invasiveness and metastasis of HCC. Detection of the aberrant methylation of DLC-1 gene from HCC patients might not only offer an effective method for the auxiliary earlier diagnosis of the invasiveness and metastasis, but also serve as an objective target for HCC therapies. No significant financial relationships to disclose.
PET/CT Before Autologous Stem Cell Transplantation Predicts Outcome In High-Risk, Relapsed Follicular Lymphoma
Authors: Marion Alcantara, Jehan Dupuis, Michel Meignan, Anne Julian, Stephanie Becker, Anne Huynh, Corinne Haioun, Herve Tilly, Loic Ysebaert
Journal: Blood (2013)
Evaluation of prognostic factors in chemotherapy of recurrent brain tumors.
Authors: R T Eagan, M Scott
Journal: Journal of Clinical Oncology (1983)

We have evaluated the prognostic significance of several easily obtainable and commonly used factors in patients with primary brain tumors (recurrent after irradiation) undergoing chemotherapy. Age, sex, tumor grade, on-study performance score, time from initial diagnosis to initial postirradiation progression, and prior chemotherapy or no were evaluated for affects on tumor response. None of the six factors significantly correlated with response to therapy. The above six factors plus response to chemotherapy were evaluated for their affects on time to progression and survival. Tumor regression following chemotherapy most strongly correlated with prolonged time to progression and survival. A good on-study performance score (not, or only minimally, symptomatic) significantly correlated with prolonged survival, but not with prolonged time to progression. Surprisingly, tumor grade did not significantly correlate with response, time to progression, or survival. Further study is required, but initial data analyses would suggest that essentially all patients with all grades of recurrent tumor could be used in chemotherapeutic trials with proper pretreatment stratification.
Premixed Powders for Protein-Free Cell Culture Media: A Quantitative Evaluation&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Sanford, Katherine K., Hoemann, Robert E., Bryant, Jay C., Shannon, John E., Evans, Virginia J.
Journal: JNCI Journal of the National Cancer Institute (1968)

Journal Article Premixed Powders for Protein-Free Cell Culture Media: A Quantitative Evaluation Get access Katherine K. Sanford, Katherine K. Sanford National Cancer Institute,6Bethesda, Maryland 20014; American Type Culture Collection, Rockville, Maryland 20852 Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert E. Hoemann, Robert E. Hoemann National Cancer Institute,6Bethesda, Maryland 20014; American Type Culture Collection, Rockville, Maryland 20852 Search for other works by this author on: Oxford Academic PubMed Google Scholar Jay C. Bryant, Jay C. Bryant National Cancer Institute,6Bethesda, Maryland 20014; American Type Culture Collection, Rockville, Maryland 20852 Search for other works by this author on: Oxford Academic PubMed Google Scholar John E. Shannon, John E. Shannon National Cancer Institute,6Bethesda, Maryland 20014; American Type Culture Collection, Rockville, Maryland 20852 Search for other works by this author on: Oxford Academic PubMed Google Scholar Virginia J. Evans Virginia J. Evans National Cancer Institute,6Bethesda, Maryland 20014; American Type Culture Collection, Rockville, Maryland 20852 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 40, Issue 5, May 1968, Pages 895–905, https://doi.org/10.1093/jnci/40.5.895 Published: 01 May 1968 Article history Received: 21 July 1967 Accepted: 03 November 1967 Published: 01 May 1968
Role of coagulation pathways and treatment with activated protein C in hyperoxic lung injury
Authors: M R Looney, C T Esmon, M A Matthay
Journal: Thorax (2008)

<h3>Background:</h3> Activated protein C (APC) significantly decreases mortality in severe sepsis, but its role in acute lung injury from non-infectious aetiologies is unclear. The role of APC in hyperoxic acute lung injury was tested by studying the physiology of lung injury development, measurement of key coagulation proteins and treatment with murine APC (mAPC). <h3>Methods:</h3> Mice were continuously exposed to &gt;95% oxygen and lung injury was assessed by extravascular lung water, lung vascular protein permeability and alveolar fluid clearance. Coagulation proteins were measured in bronchoalveolar lavage (BAL) fluid and plasma. Recombinant mAPC was administered in preventive and treatment strategies. <h3>Results:</h3> Hyperoxia produced dramatic increases in lung vascular permeability and extravascular lung water between 72 and 96 h. Lung fluid balance was also adversely affected by progressive decreases in basal and cAMP-stimulated alveolar fluid clearance. Plasma levels of APC decreased at 72 h and were 90% depleted at 96 h. There were significant increases in BAL fluid levels of thrombomodulin, thrombin-antithrombin complexes and plasminogen activator inhibitor-1 at later time points of hyperoxia. Lung thrombomodulin expression was severely decreased during late hyperoxia and plasma levels of APC were not restored by excess thrombin administration. Administration of recombinant mAPC failed to improve indices of lung injury. <h3>Conclusions:</h3> Hyperoxic acute lung injury produces procoagulant changes in the lung with a decrease in plasma levels of APC due to significant endothelial dysfunction. Replacement of mAPC failed to improve lung injury.
Abstract 15492: Imaging Oxidative Stress in Unstable Atherosclerotic Plaque With Iodine-125-Labeled 4-Hydroxy-2-Nonenal in vivo
Authors: Tomoki Doue, Eri Iwai-Kanai, Katsuichi Ohtsuki, Satoaki Matoba, Kazuma Ogawa, Hiroaki Matsubara
Journal: Circulation (2010)

Introduction: Oxidative stress contributes to the progress of atherosclerosis as inflammation, serum lipid overload, and aging do. The early identification of unstable atherosclerotic plaque, which...
Post-Transplantation Cyclophosphamide (PT-CY) After Myeloablative Conditioning Regimen (MAC) In Unmanipulated Haploidentical Bone Marrow Transplantation (hBMT) Is Highly Effective As Gvhd Prophylaxis and Disease Free Survival In Pediatric and Adult Patients With High Risk Leukemia
Authors: Maria Domenica Simone, Anna Proia, Alessandro Severino, Alison Shardlow, Novella Natale, Francesca Spirito, Mariagrazia Garzia, Barbara Montante, Anna Locasciulli, Ignazio Majolino
Journal: Blood (2013)
Phase I/II trial of PIXY321 to enhance engraftment following autologous bone marrow transplantation for lymphoid malignancy.
Authors: J M Vose, J E Anderson, P J Bierman, F R Appelbaum, J R Anderson, L Garrison, M E Lebsack, J O Armitage
Journal: Journal of Clinical Oncology (1996)

PURPOSE A phase I/II study of PIXY321 following high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT) was conducted to evaluate the safety and clinical potential of this agent. PATIENTS AND METHODS Fifty patients with Hodgkin's disease or non-Hodgkin's lymphoma (NHL) undergoing HDT and ABMT received PIXY321 post-ABMT in doses that ranged from 50 to 1,000 micrograms/m2/d either as intravenous (i.v.) or subcutaneous (SC) dosing until engraftment was reached. RESULTS If all doses are considered together, the median time to reach an absolute neutrophil count (ANC) &gt; or = 500/microL was 18 days and the median time to platelet transfusion independence was 21 days. At the estimated optimum dose of 750 micrograms/m2/d by SC injection once daily, the median time to reach an ANC &gt; or = 500/microL was 15 days and the median time to platelet transfusion independence was 16 days. Historical control patients who received granulocyte-macrophage colony-stimulating factor (GM-CSF) had a median time to an ANC &gt; or = 500/microL of 19 days and a median time to platelet independence of 26 days. CONCLUSION The administration of PIXY321 post-ABMT was generally well tolerated and resulted in prompt engraftment in the majority of patients who underwent HDT and ABMT for lymphoid malignancies. The optimum dose and route of administration of PIXY321 suggested by this trial was 750 micrograms/m2/d by once-daily SC injection. Compared with historical control patients who received 2-hour i.v. GM-CSF, patients who received PIXY321 at 750 micrograms/m2/d by SC injection once daily had an improvement in the median days to neutrophil and platelet engraftment by 4 and 10 days, respectively.
Phase Ii Trial of Epidermal Growth Factor Ointment for Patients with Erlotinib-Related Skin Effects
Authors: S.Y. Oh, I.G. Hwang, J. Lee, M.J. Park, S. Lee, S. Kim, K. Song, C.H. Son, J.H. Kang, M.H. Kang, H.G. Kim, Y.S. Park, J. Sun, H.J. Kim, C.K. Kim, S.Y. Yi, J. Jang, K. Park, H. Kim
Journal: Annals of Oncology (2014)
Studies on the Epidemiology of Bovine Leukemia&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN2"&gt;3&lt;/xref&gt;
Authors: G H Conner, J A LaBelle, R F Langham, M Crittenden
Journal: JNCI Journal of the National Cancer Institute (1966)

Characteristics of a female bovine population for a 19-county area of Michigan are defined. Cases of bovine leukemia in dairy cattle for this area are reported for the years 1962-65. The reported annual leukemia incidence for female Holstein cattle is 19 per 100,000. Reliable incidence rates could not be computed for the other four dairy breeds, since they comprised only 11 percent (approximately 50,000) of the dairy cattle population. An age-specific incidence graph shows a rather consistent increase in incidence as age advances, reaching 36 cases per 100,000 Holstein animals 8 years of age and over. The evidence indicates that size of herd has an influence on the incidence rate of leukemia--the rate being higher in large herds than in small.
Kinetics of hemodiafiltration. II. Clinical characterization of a new blood cleansing modality. 1975.
Authors: L W Henderson, C K Colton, C A Ford, J P Bosch
Journal: Journal of the American Society of Nephrology (1997)

Journal of the American Society of Nephrology : JASN 8(3):p 494-508, March 1997. | DOI: 10.1681/ASN.V83494
Abstract 4577: Mitagation of potassium dichromate micronuclei induction and kidney damage by ethanol extract of Moringa oleifera in Swiss albino rats
Authors: Kazeem A. Akinwum, Ayobami W. Adedoja, Osifeso O. Osifeso, Adenike M. Adegboyega, Deborah O. Aralamo, Olaitan O. David, Kazeem A. Akinwumi
Journal: Cancer Research (2015)

Abstract Chromate (VI) compounds are human carcinogen. Exposure by inhalation or ingestion causes lung and intestinal cancers. Current therapy has side effects, necessitating the search for antidote from medicinal plant such as Moringa oleifera (M.oleifera). This study was undertaken to evaluate the effect of ethanol extract of M. oleifera on potassium dichromate (K2Cr2O7) induced clastogenicity and kidney damage. Leaves of M.oleifera were air dried, powdered, extracted with ethanol and phytochemical analysis carried out. Thirty male rats were grouped into 6 of 5 animals each. Negative and positive control rats had water and 12mg/kg K2Cr2O7 once per week respectively. Test rats were exposed to 3.5 and 7.0 body weight M.oleifera alone for 35 days and / or 12 mg/kg body wt K2Cr2O7 once a week before they were sacrificed. The frequency of micronucleated polychromatic erythrocytes (mPCEs) was monitored in the bone marrow while creatinine and urea levels were assessed in the serum. Kidney superoxide dismutase (SOD), glutathione S-transferase (GST) and malondialdehyde (MDA) levels were also determined. K2Cr2O7 significantly (p &amp;lt;0.05) increased mPCEs and urea while creatinine was decreased when compared with control. MDA was also markedly increased, while SOD and GST were significantly reduced. Severe kidney damage was observed in the same sets of animals. However, M.oleifera mitigated the toxicity by reversing the markers towards that of control. M.oleifera is rich in flavonoids and phenolics which may account for the observed .protection. The results suggest that extract of M.oleifera has valuable potentials in the treatment/management of chromate (VI) toxicity Note: This abstract was not presented at the meeting. Citation Format: Kazeem A. Akinwum, Ayobami W. Adedoja, Osifeso O. Osifeso, Adenike M. Adegboyega, Deborah O. Aralamo, Olaitan O. David, Kazeem A. Akinwumi. Mitagation of potassium dichromate micronuclei induction and kidney damage by ethanol extract of Moringa oleifera in Swiss albino rats. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4577. doi:10.1158/1538-7445.AM2015-4577
Systemic small sized vessel vasculitis after massive antigen inhalation
Authors: L Mouthon, M Khaled, P Cohen, L Guillevin, J F Subra
Journal: Annals of the Rheumatic Diseases (2001)

We and others have proposed that desensitisation, vaccination, or inhalation of antigens by asthmatic patients may trigger Churg-Strauss syndrome (CSS).1-4 Few observations of vasculitis occurring immediately after massive inhalation of a presumed antigen have been published.2 We describe here four patients who experienced acute onset of systemic vasculitis after massive antigen inhalation.

Case 1: Several hours after massively inhaling dark diesel fumes, a 55 year old man developed rapid onset dyspnoea, sinusitis, and high fever, which regressed with short term steroid treatment. After three months he complained of bilateral foot drop, which was found to be due to mononeuritis multiplex in the left peroneal nerve upon clinical examination. The erythrocyte sedimentation rate was 72 mm/1st h, white blood cell count was 16.12×109/l,3 with 1870 eosinophils, serum creatinine 170 μmol/l; proteinuria 0.7 g/day, and microscopic haematuria. Specific anti-myeloperoxidase perinuclear labelling antineutrophil cytoplasmic antibodies (ANCA) were detected (30 IU). A neuromuscular biopsy showed necrotising vasculitis of the vasa nervorum and small sized muscle vessels, together with granulomas. Renal biopsy showed …
Training the next generation of biomedical investigators in glycosciences
Authors: Peter Agre, Carolyn Bertozzi, Mina Bissell, Kevin P. Campbell, Richard D. Cummings, Umesh R. Desai, Mary Estes, Terence Flotte, Guy Fogleman, Fred Gage, David Ginsburg, Jeffrey I. Gordon, Gerald Hart, Vincent Hascall, Laura Kiessling, Stuart Kornfeld, John Lowe, John Magnani, Lara K. Mahal, Ruslan Medzhitov, Richard J. Roberts, Robert Sackstein, Rita Sarkar, Ronald Schnaar, Nancy Schwartz, Ajit Varki, David Walt, Irving Weissman
Journal: Journal of Clinical Investigation (2016)

This position statement originated from a working group meeting convened on April 15, 2015, by the NHLBI and incorporates follow-up contributions by the participants as well as other thought leaders subsequently consulted, who together represent research fields relevant to all branches of the NIH. The group was deliberately composed not only of individuals with a current research emphasis in the glycosciences, but also of many experts from other fields, who evinced a strong interest in being involved in the discussions. The original goal was to discuss the value of creating centers of excellence for training the next generation of biomedical investigators in the glycosciences. A broader theme that emerged was the urgent need to bring the glycosciences back into the mainstream of biology by integrating relevant education into the curricula of medical, graduate, and postgraduate training programs, thus generating a critical sustainable workforce that can advance the much-needed translation of glycosciences into a more complete understanding of biology and the enhanced practice of medicine.
Psychosocial impact of cancer in Moroccan adolescents and young adults.
Authors: H. Errihani, L. Boulaamane, I. Lalya, S. Kharmoum, I. Essadi, H. Mrabti, N. Berrada
Journal: Journal of Clinical Oncology (2010)

e19649 Background: Imaginary concept of cancer is different in adolescent and young adult. North African young patients are underrepresented in the psychosocial cancer literature The purpose of this study was to describe the specific psychosocial effects of cancer on adolescent and young adult in Moroccan population in order to help physicians educate and counsel future young patients and their families. Methods: During the period from January to July 2009, patients aged between 15 and 30 years with histologically confirmed cancer, were interviewed by a questionnaire covering socio-epidemiological characteristics, repercussions of disease on physical, psychic, sexual and religious practices. Results: One hundred fifty patients were approached in the National Institute of Oncology in Rabat, Morocco. There were 54% females, 70% from urban areas, 24% were illiterates, 30% married and 86% were living with their family. Naso-pharyngeal cancer was the most common on male population, and breast cancer was the first location on females. Cancer was localised in 65% of cases. Moderate depression was present in 62% of cases, death anxiety in 33%, mental fatigue in 82% and 6% thinks to suicide. Only 6,5% of patients were followed by a psychologist. Family and friends support was present in 90% and 48%. 15% of women were divorced or were abandoned by their husbands. Romantic relationship with boyfriend or girlfriend had strengthen in 12% of patients and decreased in 5%.The majority of adolescents kept sexual desire despite decreased frequency of sex in 80% All patients were Muslims, 48% were practitioners before diagnosis, 66% reported a change in their degree of faith in God manifested by:regular practice of prayer in 60%, reading or listening to the Quran in 82%, the port of “Hijab” in 89% of young women. Toxic habits increased in 11% and appeared in 5,5%. Traditional medicine was tried by 27% of patients. Conclusions: These results indicated that Moroccan young patients face significant emotional and social changes and difficulties following cancer. Although family and friend support were often present, specific psychological care should be established to help them. No significant financial relationships to disclose.
Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases.
Authors: K Shulman, S Rosen, K Tognazzi, E J Manseau, L F Brown
Journal: Journal of the American Society of Nephrology (1996)

Vascular permeability factor (VPF), also known as vascular endothelial growth factor (VEGF), is a potent enhancer of microvascular permeability and a selective endothelial cell growth factor. In normal human kidney, VPF/VEGF mRNA and protein are strongly expressed by visceral glomerular epithelial cells, and VPF/VEGF may be an important regulator of glomerular endothelial cell function. This study examined 47 renal biopsies from patients with a variety of glomerular diseases for expression of VPF/VEGF mRNA and protein by in situ hybridization and immunohisto-chemistry. In many glomerular diseases, VPF/VEGF-expressing cells were decreased in number or absent in areas of focal or global glomerular sclerosis. Decreased numbers of VPF/VEGF-expressing cells in glomeruli were also noted in amyloidosis, diabetes, crescentic glomerulonephritis, and diffuse endocapillary proliferative glomerulonephritis associated with systemic lupus erythematosus. Normally, release of VPF/ VEGF must be under strict control because it is some 50,000 times more potent than histamine as an inducer of microvascular permeability. Damage to visceral epithelial cells in a variety of glomerular diseases has the potential for releasing relatively large amounts of VPF/VEGF locally, leading to increased glomerular permeability. In addition, because VPF/ VEGF is also an endothelial growth factor, the loss of normal, controlled secretion of VPF/VEGF after damage to visceral epithelial cells could lead to important alterations in glomerular endothelial cell function.
Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Authors: V J Land, J J Shuster, W M Crist, Y Ravindranath, M B Harris, R A Krance, D Pinkel, D J Pullen
Journal: Journal of Clinical Oncology (1994)

PURPOSE To compare efficacy and toxicity of two schedules of intermediate-dose methotrexate (IDM) and cytarabine (Ara-C) in remission consolidation of childhood acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS In 1986, the Pediatric Oncology Group (POG) began a randomized trial to test two schedules of consolidation chemotherapy in children with newly diagnosed B-precursor cell ALL. MTX and Ara-C were given as overlapping 24-hour infusions. The dose and sequence of MTX and Ara-C administration were based on a preclinical model that had demonstrated synergism between these two agents. Two hundred fifteen patients in complete remission were randomized to front-loading consolidation therapy in which six MTX/Ara-C infusions were administered at 3-week intervals from the 7th through the 19th week of therapy. Two hundred thirteen patients in complete remission were randomized to receive standard consolidation therapy in which the six MTX/Ara-C infusions were given every 12 weeks from the 7th through the 67th week of therapy. RESULTS Both regimens produced similar rates of adverse side effects, except for a higher incidence of CNS toxicity in individuals randomized to the front-loading arm (32 of 215 v 12 of 213 patients, P = .002). Leukoencephalopathy occurred in three patients on the front-loading regimen and was permanent in one. By Kaplan-Meier analysis, the probability of continuing in complete remission for 5 years was 79% (SE = 5%) and 85% (SE = 5%) for good-risk patients, and 66% (SE = 6%) and 61% (SE = 7%) for poor-risk patients randomized to front-loading and standard regimens, respectively. CONCLUSION Although differences in complete remission durations were not statistically significant by log-rank analysis (P = .62 for good-risk patients, .89 for poor-risk patients, and .99 overall), the results are comparable to those in previous studies using more toxic agents as components of remission consolidation therapy.